Akeso
Works in Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Musculoskeletal · Oncology · Renal & urogenital · Respiratory · Women's health
Akeso is a clinical trial sponsor. It has 83 active clinical trials with 21,707 planned participants, across 12 therapeutic areas. Since 2021 it has completed 59 trials and stopped 8 early.
Trial track record · since 2021
Pipeline · 83 active trials
| Stage | Trial | Status |
|---|---|---|
On the market · 1 product
- PENPULIMAB-KCQX penpulimab-kcqx · BLA 761258 · prescription
Questions about Akeso
Akeso is lead sponsor of 83 active clinical trials on ClinicalTrials.gov, with 21,707 planned participants, in Dermatology, ENT, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 59 trials and stopped 8 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Akeso; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Products come from FDA's drug application database and, for vaccines, cell and gene therapies and blood products, FDA's Purple Book of licensed biologics; checked 2026-09-25.
Approve Suite is not affiliated with Akeso. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.